Trials / Recruiting
RecruitingNCT03200379
Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 150,000 (estimated)
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
To determine the treatment efficacy, safety and long-term outcomes of chronic hepatitis C patients receiving directly acting antivirals in Taiwan
Detailed description
The National Health Insurance Administration (NHIA) in Taiwan supports the use of antivirals against CHC. Recently, the introduction of directly acting antivirals (DAA) has markedly improved the treatment adherence, efficacy and safety issues in well-designed clinical trials. However, the real world community effectiveness and long-term benefits of DAA for HCV treatments remain to be determined. Since the NHIA in Taiwan has reimbursed the DAA in the treatment of chronic hepatitis C (CHC) patients in the near future, establishment of a well prospectively designed registry policy is demanded in the national level to explore the unmet needs of HCV control in Taiwan. The primary purpose of the study is to establish a nationwide registry of patients undergoing antiviral treatment with DAA regimens for CHC at both academic and community practices. Based on this database, the clinical gaps regarding to treatment guidelines and management of adverse events will be identified. The registry system will be established as a research network and provide sufficient high-quality clinical information for investigators in Taiwan.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | directly acting antivirals (DAAs) | Eligible subjects would be those CHC patients who receive approved DAA in the daily practice in Taiwan. No clinical developing medications will be allocated patients. |
Timeline
- Start date
- 2017-06-15
- Primary completion
- 2037-06-15
- Completion
- 2037-06-15
- First posted
- 2017-06-27
- Last updated
- 2022-04-08
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT03200379. Inclusion in this directory is not an endorsement.